BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Antibiotics are one of the most common medicines in the world, with about 236 million prescriptions in the U.S. | The company ...

IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient ...

Remedee Labs, a startup based in Paris, France, has received a European approval for its device-based approach to treating ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

A bipolar disorder research initiative backed by Big Tech has announced $36 million in new funding for research into the ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.